FY2025 EPS Estimates for Maximus Lifted by Zacks Research

Maximus, Inc. (NYSE:MMS - Free Report) - Zacks Research upped their FY2025 earnings per share estimates for shares of Maximus in a report issued on Thursday, February 27th. Zacks Research analyst R. Department now anticipates that the health services provider will earn $6.00 per share for the year, up from their prior forecast of $5.84. The consensus estimate for Maximus' current full-year earnings is $6.15 per share. Zacks Research also issued estimates for Maximus' Q1 2026 earnings at $1.34 EPS, Q2 2026 earnings at $1.26 EPS, Q3 2026 earnings at $1.61 EPS, Q4 2026 earnings at $1.36 EPS and Q1 2027 earnings at $1.12 EPS.

Several other brokerages have also issued reports on MMS. StockNews.com lowered shares of Maximus from a "buy" rating to a "hold" rating in a research report on Friday, February 14th. Raymond James upgraded Maximus from a "market perform" rating to an "outperform" rating and set a $90.00 price objective for the company in a report on Thursday, January 2nd.

Maximus Price Performance

MMS stock traded down $0.03 during midday trading on Monday, reaching $67.97. The company had a trading volume of 723,383 shares, compared to its average volume of 473,416. The firm has a 50-day moving average price of $72.91 and a 200-day moving average price of $80.49. The company has a market capitalization of $3.85 billion, a P/E ratio of 14.62 and a beta of 0.72. Maximus has a 1 year low of $63.77 and a 1 year high of $93.97. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.72 and a quick ratio of 1.72.

Remove Ads

Maximus (NYSE:MMS - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The health services provider reported $1.61 EPS for the quarter, topping the consensus estimate of $1.39 by $0.22. Maximus had a return on equity of 21.95% and a net margin of 5.28%.

Institutional Investors Weigh In On Maximus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Maximus by 3.2% in the fourth quarter. Vanguard Group Inc. now owns 6,548,284 shares of the health services provider's stock valued at $488,829,000 after acquiring an additional 205,564 shares during the period. Mackenzie Financial Corp grew its stake in shares of Maximus by 2.0% in the fourth quarter. Mackenzie Financial Corp now owns 2,782,150 shares of the health services provider's stock worth $207,687,000 after purchasing an additional 55,583 shares during the last quarter. Geode Capital Management LLC increased its holdings in Maximus by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,525,159 shares of the health services provider's stock valued at $142,109,000 after purchasing an additional 21,532 shares during the period. Dimensional Fund Advisors LP raised its position in Maximus by 14.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,406,592 shares of the health services provider's stock valued at $105,001,000 after purchasing an additional 177,075 shares during the last quarter. Finally, Van Berkom & Associates Inc. raised its position in Maximus by 8.5% during the 4th quarter. Van Berkom & Associates Inc. now owns 1,256,418 shares of the health services provider's stock valued at $93,792,000 after purchasing an additional 98,264 shares during the last quarter. 97.21% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Ilene R. Baylinson sold 14,500 shares of Maximus stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $68.14, for a total value of $988,030.00. Following the transaction, the insider now owns 2,512 shares in the company, valued at approximately $171,167.68. The trade was a 85.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond B. Ruddy bought 3,490 shares of the stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $71.46 per share, with a total value of $249,395.40. Following the purchase, the director now owns 112,520 shares in the company, valued at $8,040,679.20. The trade was a 3.20 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 7,008 shares of company stock worth $497,835 in the last 90 days. 1.60% of the stock is owned by company insiders.

Maximus Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 28th. Stockholders of record on Saturday, February 15th were issued a $0.30 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.77%. Maximus's payout ratio is 25.81%.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.